Supriya Lifescience Limited IPO
Supriya Lifescience Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹265–₹274 per share to raise ₹700 crore. The issue was subscribed 71.51× overall (QIBs 31.83×, NIIs 161.22×, retail 56.01×). It listed on 28 Dec 2021 at ₹421 and closed its first day at ₹391, a listing gain of +42.6% versus the ₹274 issue price. It now trades around ₹847 (+209.2% versus the issue price).
Frequently asked questions
- How many times was the Supriya Lifescience Limited IPO subscribed?
- The Supriya Lifescience Limited IPO was subscribed 71.51× overall — 31.83× in the QIB category, 161.22× among non-institutional investors, 56.01× in retail.
- What were the Supriya Lifescience Limited IPO listing gains?
- Supriya Lifescience Limited listed on 28 Dec 2021 at ₹421, closing its first day at ₹391 — a listing gain of +42.6% versus the ₹274 issue price.
- What were the retail allotment odds for the Supriya Lifescience Limited IPO?
- Retail was subscribed 56.01×, so a single-lot application had roughly a 1.8% chance of allotment (about 1 in 56), and allotment was finalised on 22 Dec 2021.
- What was the price band and lot size of the Supriya Lifescience Limited IPO?
- The price band was ₹265–₹274 per share, with a minimum lot of 54 shares (₹14,796 at the upper band).
- Who were the registrar and lead manager for the Supriya Lifescience Limited IPO?
- Link Intime India Private Limited was the registrar, and ICICI Securities was the book-running lead manager.